Investors

Brain+ TO 4 warrant
exercise now!

Deadline on….

Building the world’s first scalable dementia care platform to help people affected by dementia live better lives

At Brain+, we care about people affected by dementia. We also care about our shareholders, and it is important for us to provide open and transparent information about our business as we work towards achieving our mission.

We are pioneers in the development of digital Cognitive Stimulation Therapy (CST), the global standard for non-drug treatment of people with dementia. Based on our expertise in software-based training tools, our deep understanding of brain functioning, and a strong network of partnerships in the dementia space, we are building Ayla, the world’s first scalable dementia care platform.

Our first product, Ayla – your CST assistant is certified as a medical device in the United Kingdom and available for sale in the United Kingdom and Denmark.

Group Cognitive Stimulation Therapy (CST) session using digital CST-Assistant (2)

Latest company releases

We strive to keep our investors and other stakeholders informed about our business activities and on other news of relevance for Brain+

Brain+
Invitation to Investor Webinar on Monday 25th of November at 15:30: Update on commercial status and new opportunities
Read more
Brain logo
Brain+ closes new Danish municipality sales contract on Ayla – your CST Assistant
Read more
Brain new logo
Brain+ progresses UK commercial outreach and hosts the first of a series of webinars on the value of Cognitive Stimulation Therapy
Read more

Latest investor webinars

Company releases

Financial
reports

Brain+
in the news